Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 281

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 281
---
5b and Note 5c).

| NOTE 15:- | SUBSEQUENT EVENTS |

| A. | In the first quarter                                                                       
 of 2025, the Company received an additional loan in the amount of $100 under a bridge loan 
 agreement (see also Note 5). As of March 31, 2025, the Company received $350 under bridge  
 loan agreements.                                                                           |

<div align='center'>F-29</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 15:- | SUBSEQUENT EVENTS (Cons.) |

| 1. | A forward share                                                                                  
 split at a ratio of a two and a half-for-one (2.5-for-1) of the Ordinary Shares and preferred    
 shares. As a result of the Split, for every one (1) share of share either issued and outstanding 
 will be granted two and a half (2.5) new Ordinary Shares or preferred shares, as applicable.     |

| 2. | Contingent upon the                                                                        
 implementation of an initial public offering, the chairman of the Company’s board of       
 directors will be eligible to: (i) annual compensation of $250, to be paid on a quarterly  
 basis; (ii) a grant of 283,532 options with an exercise price of NIS 0.01; and (iii) at a  
 Qualified IPO (as defined below), a cash payment of $500. In addition, the holdings of the 
 chairman of the Company’s board of directors shall not be diluted any lower than 9.98%     
 as a result of any IPO with a total proceeds of no less than $6,000 (a “Qualified IPO”).   |

| 3. | Increase of authorized                             
 share capital from 3,000,000 to 22,500,000 shares. |

| 4. | Cancellation of                                                          
 the Company’s nominal value per each Ordinary Share and preferred share. |

| D. | In April 2025, the                                                                             
 Company entered into bridge loan agreements (the “April 2025 Loans” or "April                  
 2025 Loan Agreements"), pursuant to which the Company obtained bridge loans from the           
 lenders thereto including certain related parties, including the Company's chairman of the     
 board of directors, a member of the Company's board of directors, and a director nominee.